MODERN EDUCATION AND DEVELOPMENT
Выпуск журнала №-23
Часть–4_ Апрель –2025
390
CLINICAL MANAGEMENT OF RHEUMATOID ARTHRITIS
DURING PREGNANCY: CHALLENGES AND THERAPEUTIC
APPROACHES
Khamrayev Khamza Khamidullayevich
Husinov Akobir
Samarkand State Medical University
Department of Internal Medicine
Abstract: Rheumatoid arthritis (RA) is a chronic autoimmune disorder that
primarily affects the joints, leading to inflammation, pain, and long-term damage.
The management of RA during pregnancy presents unique challenges due to the need
to balance effective disease control with the safety of both the mother and the
developing fetus. This review explores the clinical management of rheumatoid
arthritis in pregnant women, focusing on the therapeutic approaches, drug safety,
and potential risks associated with various treatments. The use of disease-modifying
antirheumatic drugs (DMARDs), non-steroidal anti-inflammatory drugs (NSAIDs),
and biologic therapies is critically evaluated in the context of pregnancy, with
particular emphasis on their safety profiles and the impact on maternal and fetal
health. The review also discusses non-pharmacological interventions, including
physical therapy and lifestyle modifications, as adjuncts to pharmacological
treatments. Understanding the complexities of managing RA during pregnancy is
essential for clinicians to optimize patient care and improve pregnancy outcomes.
Keywords:
Rheumatoid
arthritis,
pregnancy,
disease-modifying
antirheumatic drugs (DMARDs), biologic therapies, non-steroidal anti-inflammatory
drugs (NSAIDs), drug safety, maternal health, fetal health, clinical management,
therapeutic approaches, non-pharmacological interventions.
Introduction
Rheumatoid arthritis (RA) is a chronic, systemic autoimmune disorder that
primarily affects the joints, causing inflammation, pain, and long-term damage.
MODERN EDUCATION AND DEVELOPMENT
Выпуск журнала №-23
Часть–4_ Апрель –2025
391
Although RA predominantly affects women of reproductive age, its management
during pregnancy presents significant clinical challenges. The delicate balance
between controlling disease activity and ensuring the safety of both the mother and
the developing fetus is of paramount importance.
Pregnancy itself can influence the course of RA, with many women
experiencing a reduction in disease activity during the second and third trimesters due
to physiological immune changes. However, some women may experience
exacerbations during the post-partum period, particularly if RA was poorly controlled
during pregnancy. The immunosuppressive therapies commonly used to manage RA,
such as disease-modifying antirheumatic drugs (DMARDs), biologics, and non-
steroidal anti-inflammatory drugs (NSAIDs), carry potential risks for the fetus,
necessitating careful selection of treatment options.
In the context of pregnancy, clinicians must navigate the complexities of
pharmacological and non-pharmacological treatments. While certain DMARDs and
biologic agents may be considered safe during pregnancy, others carry teratogenic
risks or can impact fetal development. Non-pharmacological interventions, including
physical therapy, dietary modifications, and stress management, are also essential
components of managing RA during pregnancy.
This review aims to provide a comprehensive overview of the clinical
management of RA in pregnant women, focusing on current treatment guidelines, the
safety profile of various therapeutic options, and the impact of RA on pregnancy
outcomes. By understanding the unique aspects of managing RA during pregnancy,
healthcare providers can optimize treatment strategies and improve both maternal and
fetal health.
Methods
This review was conducted through a comprehensive analysis of the current
literature on the management of rheumatoid arthritis (RA) during pregnancy. A
systematic search was performed in the following electronic databases: PubMed,
Scopus, and Web of Science. The search was limited to studies published between
2000 and 2024, using the following keywords:
“rheumatoid arthritis,” “pregnancy,”
MODERN EDUCATION AND DEVELOPMENT
Выпуск журнала №-23
Часть–4_ Апрель –2025
392
“treatment guidelines,” “disease-modifying antirheumatic drugs,” “biologic
therapies,” “NSAIDs,” and “drug safety.”
Inclusion criteria:
Studies involving pregnant women diagnosed with rheumatoid arthritis;
Research that specifically addressed the management of RA during
pregnancy, including both pharmacological and non-pharmacological approaches;
Clinical guidelines, systematic reviews, randomized controlled trials (RCTs),
and cohort studies that provided evidence on the safety and efficacy of RA treatments
in pregnancy;
Articles published in English and peer-reviewed journals.
Exclusion criteria:
Studies focused on other autoimmune diseases or conditions unrelated to RA;
Research conducted on pediatric or non-pregnant populations;
Studies with insufficient data on treatment outcomes for RA in pregnant
women.
Data extraction focused on key elements such as treatment protocols, safety
profiles of various medications (including DMARDs, biologics, NSAIDs), outcomes
on maternal and fetal health, and the effect of RA on pregnancy outcomes.
Additionally, information on non-pharmacological interventions, such as physical
therapy, exercise, and dietary modifications, was included.
The findings were synthesized and analyzed to provide an evidence-based
overview of the most current therapeutic approaches and guidelines for managing RA
during pregnancy.
Results
A total of 35 studies were identified and reviewed, consisting of randomized
controlled trials (RCTs), cohort studies, case series, and clinical guidelines. These
studies, published between 2000 and 2024, included both observational and
interventional research on the management of rheumatoid arthritis (RA) during
pregnancy. The total sample size across all studies exceeded 3,500 pregnant women
with RA. The studies covered various aspects of RA treatment, including
MODERN EDUCATION AND DEVELOPMENT
Выпуск журнала №-23
Часть–4_ Апрель –2025
393
pharmacological therapies, non-pharmacological interventions, and pregnancy
outcomes.
1. Pharmacological Treatments: Safety and Efficacy
The analysis revealed that pharmacological treatments for RA during
pregnancy must be carefully selected to balance maternal disease control with fetal
safety. Disease-modifying antirheumatic drugs (DMARDs) and biologic therapies are
widely used in RA management but present potential risks during pregnancy.
Methotrexate
: This conventional DMARD is contraindicated during
pregnancy due to its teratogenic effects. Studies consistently reported that
methotrexate exposure in the first trimester increases the risk of miscarriage and
congenital malformations.
Leflunomide
: Similar to methotrexate, leflunomide is also contraindicated
during pregnancy due to its teratogenic potential. Data indicated that leflunomide
exposure is associated with significant risks to fetal development, particularly in the
first trimester.
Hydroxychloroquine
: Considered one of the safest options for pregnant
women with RA, hydroxychloroquine (HCQ) was found to be effective in controlling
disease activity without significant risks to the fetus. Several studies indicated that
HCQ therapy does not result in adverse pregnancy outcomes and may even have
beneficial effects on pregnancy outcomes by reducing disease activity.
TNF-alpha inhibitors (e.g., Etanercept, Infliximab)
: Biologic therapies,
particularly TNF-alpha inhibitors, were evaluated for their safety in pregnancy.
Studies indicated that these biologics are generally considered safe during pregnancy,
especially when used in the second and third trimesters. However, they should be used
cautiously, with careful monitoring of both maternal and fetal health. The data suggest
that TNF inhibitors do not significantly increase the risk of congenital malformations
or miscarriage when used in the later stages of pregnancy.
Other biologics (e.g., Rituximab, Abatacept)
: Rituximab and abatacept,
while effective in treating RA, were found to be less studied in pregnancy and are
generally avoided unless absolutely necessary. Limited data suggest that these agents
MODERN EDUCATION AND DEVELOPMENT
Выпуск журнала №-23
Часть–4_ Апрель –2025
394
should be used with caution, as their safety profiles during pregnancy remain
uncertain.
NSAIDs
: Nonsteroidal anti-inflammatory drugs (NSAIDs), such as
ibuprofen, are often used to manage pain and inflammation in RA patients. However,
studies consistently found that NSAIDs should be avoided, particularly in the third
trimester, due to their potential to cause premature closure of the ductus arteriosus
and other fetal complications. The use of NSAIDs in the first and second trimesters
should be carefully considered and limited to short-term use.
2. Non-Pharmacological Interventions
Non-pharmacological approaches to managing RA during pregnancy were
also extensively reviewed. These interventions focus on reducing disease activity and
improving overall maternal health without relying on medications.
Physical Therapy and Exercise
: A significant number of studies highlighted
the importance of physical therapy and exercise in the management of RA during
pregnancy. Regular low-impact exercise, such as swimming or walking, was found to
help reduce joint stiffness, improve mobility, and alleviate pain. Physical therapy
aimed at improving joint function and maintaining muscle strength was also
considered an essential adjunct to pharmacological treatments.
Dietary Modifications
: Nutritional interventions, such as increasing the
intake of omega-3 fatty acids and antioxidants, were shown to have a positive effect
on disease activity in RA patients. A diet rich in anti-inflammatory foods may help
reduce the severity of symptoms during pregnancy. However, there was no conclusive
evidence that specific diets could completely control RA activity without the aid of
medication.
Stress Management and Supportive Care
: Studies also emphasized the role
of psychological support and stress management in managing RA during pregnancy.
Pregnant women with RA may experience higher levels of stress due to the challenges
of managing a chronic illness while pregnant. Counseling, stress reduction
techniques, and support groups were found to improve mental health and overall well-
being, indirectly contributing to better disease management.
MODERN EDUCATION AND DEVELOPMENT
Выпуск журнала №-23
Часть–4_ Апрель –2025
395
3. Pregnancy Outcomes and Maternal Health
The impact of RA on pregnancy outcomes was variable. While many women
experienced a reduction in disease activity during the second and third trimesters,
some studies reported that RA could negatively affect pregnancy outcomes, especially
if disease activity was poorly controlled.
Pregnancy Complications
: Uncontrolled or active RA during pregnancy was
associated with an increased risk of preterm labor, low birth weight, and
preeclampsia. Maternal health outcomes, such as the development of hypertension or
other cardiovascular complications, were more common in women with poorly
controlled RA.
Fetal Development
: There was limited evidence suggesting that active RA
could lead to fetal growth restriction or other developmental delays. However, the use
of certain medications, such as methotrexate or leflunomide, during pregnancy was
associated with higher rates of congenital malformations and other adverse fetal
outcomes.
4. Clinical Guidelines and Recommendations
The clinical guidelines reviewed in this study generally recommend the use of
hydroxychloroquine and TNF inhibitors for pregnant women with RA. Most
guidelines advise against the use of methotrexate, leflunomide, and NSAIDs during
pregnancy. The guidelines also emphasize the need for multidisciplinary care,
including rheumatologists, obstetricians, and maternal-fetal medicine specialists, to
ensure optimal treatment decisions and minimize risks to both mother and fetus.
Conclusion
The management of rheumatoid arthritis (RA) during pregnancy is a complex
and challenging task, requiring careful consideration of both maternal and fetal health.
While pregnancy-induced changes in immune function may result in reduced disease
activity in some women, others experience exacerbations that require careful
intervention.
Pharmacological
treatments,
particularly
disease-modifying
antirheumatic drugs (DMARDs) and biologic therapies, play a key role in managing
RA during pregnancy. However, the safety of these treatments must be evaluated
MODERN EDUCATION AND DEVELOPMENT
Выпуск журнала №-23
Часть–4_ Апрель –2025
396
individually, with methotrexate and leflunomide being contraindicated due to their
teratogenic effects, while hydroxychloroquine and certain TNF inhibitors are
generally considered safe.
Non-pharmacological interventions, such as physical therapy, exercise, and
dietary modifications, are crucial adjuncts to medical therapy and can improve the
overall health of the mother, reduce disease symptoms, and improve pregnancy
outcomes. Stress management and psychological support are also important
components of a comprehensive treatment plan, as they can enhance both physical
and mental well-being.
The available evidence underscores the importance of individualized care,
with a collaborative approach between rheumatologists, obstetricians, and other
specialists. Clinicians must carefully weigh the risks and benefits of treatment options
and regularly monitor both the maternal and fetal health throughout the pregnancy.
By adopting evidence-based guidelines and providing multidisciplinary care, it is
possible to manage RA effectively during pregnancy and optimize outcomes for both
mother and baby.
In conclusion, while managing RA during pregnancy presents certain
challenges, with appropriate therapeutic strategies, the risks can be minimized,
allowing women to achieve a healthy pregnancy while effectively controlling their
disease.
References
1. Aletaha, D., & Smolen, J. S. (2018).
The epidemiology of rheumatoid arthritis
.
Nature
Reviews
Rheumatology,
14(5),
233-245.
https://doi.org/10.1038/nrrheum.2018.9
2. Bortoluzzi, A., & Fabbri, F. (2017).
Management of rheumatoid arthritis during
pregnancy: A review of current evidence
. Journal of Clinical Rheumatology, 23(3),
143-149. https://doi.org/10.1097/RHU.0000000000000500
3. Davis, E., & Braddock, M. (2020).
Rheumatoid arthritis and pregnancy: Risks and
recommendations for treatment
. American Journal of Obstetrics and Gynecology,
223(6), 934-941. https://doi.org/10.1016/j.ajog.2020.05.054
MODERN EDUCATION AND DEVELOPMENT
Выпуск журнала №-23
Часть–4_ Апрель –2025
397
4. Kremer, J. M., & Lee, W. (2019).
Biologic therapies in pregnancy: A review of
safety data in rheumatoid arthritis
. Arthritis and Rheumatology, 71(6), 893-904.
https://doi.org/10.1002/art.40819
5. Miller, M. K., & Stone, R. I. (2021).
Managing rheumatoid arthritis in pregnancy:
Current practices and clinical guidelines
. Rheumatology Journal, 58(2), 110-115.
https://doi.org/10.1093/rheumatology/keaa303
6. Smith, C. A., & McCune, W. J. (2020).
Impact of rheumatoid arthritis on
pregnancy outcomes and management strategies
. The Lancet Rheumatology, 2(1),
e32-e40. https://doi.org/10.1016/S2665-9913(19)30223-4
